287 related articles for article (PubMed ID: 17109710)
1. Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
Nakanishi S; Kunugi H; Murray RM; Nojima S; Ogawa T; Takahashi T
Psychiatry Clin Neurosci; 2006 Dec; 60(6):751-7. PubMed ID: 17109710
[TBL] [Abstract][Full Text] [Related]
2. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.
Mori K; Nagao M; Yamashita H; Morinobu S; Yamawaki S
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):659-65. PubMed ID: 15276691
[TBL] [Abstract][Full Text] [Related]
3. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
4. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group.
Desai NM; Huq Z; Martin SD; McDonald G
Adv Ther; 1999; 16(2):78-88. PubMed ID: 10539380
[TBL] [Abstract][Full Text] [Related]
5. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets.
Normann C; Schmauss M; Bakri N; Gerwe M; Schreiner A
Pharmacopsychiatry; 2006 Nov; 39(6):209-12. PubMed ID: 17124642
[TBL] [Abstract][Full Text] [Related]
6. [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Pajonk FG; Schreiner A; Peters S; Rettig K; Degner D; Rüther E
Fortschr Neurol Psychiatr; 2003 May; 71(5):249-54. PubMed ID: 12740756
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia.
Kane JM; Potkin SG; Daniel DG; Buckley PF
J Clin Psychiatry; 2011 Feb; 72(2):194-204. PubMed ID: 20673553
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.
Fujikawa M; Togo T; Yoshimi A; Fujita J; Nomoto M; Kamijo A; Amagai T; Uchikado H; Katsuse O; Hosojima H; Sakura Y; Furusho R; Suda A; Yamaguchi T; Hori T; Kamada A; Kondo T; Ito M; Odawara T; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):755-60. PubMed ID: 18226436
[TBL] [Abstract][Full Text] [Related]
9. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
Nakajima M; Terao T; Iwata N; Nakamura J
Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
[TBL] [Abstract][Full Text] [Related]
10. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
[TBL] [Abstract][Full Text] [Related]
12. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
13. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects.
Himei A; Okamura T
Psychiatry Clin Neurosci; 2005 Oct; 59(5):556-62. PubMed ID: 16194258
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
Zink M; Kuwilsky A; Krumm B; Dressing H
J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
[TBL] [Abstract][Full Text] [Related]
16. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
[TBL] [Abstract][Full Text] [Related]
17. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
Philipp M; Lesch OM; Schmauss M; Dose M; Glaser T
Psychiatr Prax; 2003 May; 30 Suppl 2():S94-6. PubMed ID: 14509050
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia.
Suzuki T; Uchida H; Takeuchi H; Nakajima S; Nomura K; Tanabe A; Yagi G; Watanabe K; Kashima H
Hum Psychopharmacol; 2009 Dec; 24(8):628-38. PubMed ID: 19946935
[TBL] [Abstract][Full Text] [Related]
19. The influence of risperidone on cognitive functions in schizophrenia.
Barkić J; Filaković P; Radanović-Grgurić L; Koić O; Laufer D; Pozgain I; Koić E; Hotujac L
Coll Antropol; 2003; 27 Suppl 1():111-8. PubMed ID: 12955900
[TBL] [Abstract][Full Text] [Related]
20. Risperidone-related weight gain: genetic and nongenetic predictors.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
